Good podcast? Give it some love!
OncoPharmPod
OncoPharmEpisodes
Episodes of OncoPharm
Mark All
Search Episodes...
Lots of recent updates to cover this week...1. Adjuvant pembrolizumab of RCC demonstrates OS improvement in NEJM publication (DOI: 10.1056/NEJMoa2312695)2. Yet adjuvant nivolumab did not demonstrate OS improvement in the adjuvant setting.
What I learned (or relearned?) at HOPA's 2024 Annual Conference: updates in Neuro Oncology, fedratinib toxicity, and bispecific antibodies in multiple myeloma.Also, fam-trastuzumab deruxtecan (T-DXd) garnered a site-agnostic approval for HER2
Tumor Lysis Syndrome (TLS) is a foundational topic for all oncology clinicians. We discuss the what, the why, prevention, and treatment.
Discussing four papers that caught our eyes from the last few weeks:Pazopanib vs. placebo following metastatectomy. Always concerning when placebo has an OS advantage.ECOG-ACRIN E2810: https://doi.org/10.1200/JCO.23.01544Gemcitabine vs. G
Two recent publications suggest more people may be choosing non-colonoscopy screening practices in the future. One is a new stool DNA test, while the other is a blood test.How do they compare to the gold standard of colonoscopy?Cell-free D
EV-302 is finally published, and you have to squint to find any major critiques. Enfortumab bedouin + pembrolizumab fully arrives as a standard 1st-line regimen of advanced urothelial cancer.Also, nivolumab gets a 1st-line FDA approval for u
Two nice studies have been recently published in the supportive care realm.SPARED asks if we can omit dexamethasone on days 2-4 following cisplatin-based chemotherapy.D-TORCH asks if topical diclofenac can prevent capecitabine-induced hand-
An exciting new cellular therapy, lifileucel, is approved for metastatic melanoma. The FLAURA2 trial of osimertinib + chemotherapy has led to an FDA approval, but questions remain about a possible new standard of care. And a few minor updates
New updates on metastatic pancreatic cancer (NAPOLI-3), upper tract urothelial cancer (POUT), and the drug-drug interaction between ivosidenib and azole antifungals.NAPOLI 3: https://doi.org/10.1016/S0140-6736(23)01366-1POUT (final OS): htt
You know about small cell lung cancer, but let's talk about small cell carcinoma of the prostate.
In oncology we are always asking questions about which treatment option is best. And that focus on the next best treatment may prevent us from rethinking some fundamentals of current practice. Three recent studies illustrate this and made me a
...on FDA approvals for belzutifan for RCC, pembrolizumab + cisplatin/RT for cervical cancer, erdafitinib (FGFR3 alterations only) for bladder cancer.Plus, early morning ICIs (https://doi.org/10.1016/j.ejca.2024.113571)&FLAG-Ida-GO in AML f
Special guest Ryan Beechinor joins the pod to discuss his recent paper on the obstacles in the development of generic lenalidomide. It's a fantastic read, and this episode will be a fantastic listen!Link: https://doi.org/10.1016/j.jcpo.2023.1
Foundations of OncoPharm episode on lenalidomide (Revlimid) and its MOA, use, dosing, & toxicity.
A Holiday Tradition returns as we review 14 new OncoPharm drugs approved this past year and ask Keep, Re-Gift, or Return.
Small bites of updates coming out of ASH's 2023 annual meeting on CLL, multiple myeloma, and lymphoma.
Our Landmarks of OncoPharm series returns to talk about 2008's VISTA study, which ushered bortezomib into the front line setting, albeit with a now outdated alkylating agent-based backbone.VISTA (VMP vs. MP): https://www.nejm.org/doi/full/10.
The recent approval of nirogacestat, the first gamma secretase inhibitor on the market, provides a great opportunity to discuss desmoid tumors and Notch signaling.Review article: https://doi.org/10.1002/onco.13627Also, a new T-cell malignan
FDA has approved two new kinase inhibitors: one for ROS1 (+) NSCLC and one for PIK3CA/AKT/PTEN altered breast cancer.
This week's Pod dives into a new VEGF-R inhibitor, fruquintinib. We also ask if FLAURA2, osimertinib + chemotherapy in combination, will become a new standard of care in EGFR-mutated metastatic NSCLC.
Aggressive hematologic malignancy publications can be challenging to interpret and translate to clinical practice.We look at two recent studies to illustrate this point. Elderly AML: 10-day decitabine vs. 7 + 3 (https://doi.org/10.1016/S23
Out Landmarks of OncoPharm series returns to chronicle how treatment of stage III NSCLC has changed over time with an overview of three studies.1. Dillman (1990) NEJM (sequential chemo --> RT): https://doi.org/10.1056/nejm1990100432314032.
Lots of practice changing new information came out of last week's ESMO conference.This Pod is packed with updates on NSCLC, bladder cancer, gastric cancer, medullary thyroid cancer, KRAS G12C colorectal cancer.....and even bendamustine (non-E
This week we discuss the continued push to introduce 2nd generation androgen inhibitors earlier into treatment with the EMBARK trial.Nivolumab and pembrolizumab, pemrolizumab and nivolumab. Again and again. Their role (and approvals) for adj
Join Podchaser to...
- Rate podcasts and episodes
- Follow podcasts and creators
- Create podcast and episode lists
- & much more
Unlock more with Podchaser Pro
- Audience Insights
- Contact Information
- Demographics
- Charts
- Sponsor History
- and More!
- Account
- Register
- Log In
- Find Friends
- Resources
- Help Center
- Blog
- API
Podchaser is the ultimate destination for podcast data, search, and discovery. Learn More
- © 2024 Podchaser, Inc.
- Privacy Policy
- Terms of Service
- Contact Us